Literature DB >> 26877790

Synthesis of cyclic N (1)-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells.

Ahmed Mahal1, Stefano D'Errico1, Nicola Borbone1, Brunella Pinto1, Agnese Secondo2, Valeria Costantino1, Valentina Tedeschi2, Giorgia Oliviero1, Vincenzo Piccialli3, Gennaro Piccialli1,4.   

Abstract

Cyclic N (1)-pentylinosine monophosphate (cpIMP), a novel simplified inosine derivative of cyclic ADP-ribose (cADPR) in which the N (1)-pentyl chain and the monophosphate group replace the northern ribose and the pyrophosphate moieties, respectively, was synthesized. The role played by the position of the phosphate group in the key cyclization step, which consists in the formation of a phosphodiester bond, was thoroughly investigated. We have also examined the influence of the phosphate bridge on the ability of cpIMP to mobilize Ca(2+) in PC12 neuronal cells in comparison with the pyrophosphate bridge present in the cyclic N (1)-pentylinosine diphosphate analogue (cpIDP) previously synthesized in our laboratories. The preliminary biological tests indicated that cpIMP and cpIDP induce a rapid increase of intracellular Ca(2+) concentration in PC12 neuronal cells.

Entities:  

Keywords:  cIDPR analogues; calcium mobilization; cyclic ADP-ribose (cADPR); cyclization

Year:  2015        PMID: 26877790      PMCID: PMC4734301          DOI: 10.3762/bjoc.11.289

Source DB:  PubMed          Journal:  Beilstein J Org Chem        ISSN: 1860-5397            Impact factor:   2.883


Introduction

Nucleosides and nucleotides (NNs) are widely used as key intermediates and important core structures in the field of synthetic medicinal chemistry [1-2]. They represent versatile synthetic building blocks towards the synthesis of biologically relevant compounds such as antiviral and antineoplastic drugs [3-8], antibiotics and antifungal agents [9-11]. Furthermore, several NNs act as potent second messengers involved in the regulation of key metabolic pathways [12]. Among these NNs there is the cyclic ADP-ribose (cADPR 1, Figure 1), a metabolite strictly involved in the homeostasis of cellular calcium ions. cADPR is a second messenger that activates the ryanodine receptors of the sarcoplasmic reticulum and mobilizes Ca2+ ions in many cell types of protozoa, plants, animals and humans [13].
Figure 1

Structures of cADPR (1), cIDPR (2), cpIDP (3) and cpIMP (4).

Structures of cADPR (1), cIDPR (2), cpIDP (3) and cpIMP (4). Furthermore, there is a strong evidence that cADPR is an important second messenger in the nervous system where it is involved in the handling of Ca2+ ions that control several functions. Indeed, the administration of cADPR to cell cultures produces three patterns of response in terms of variation of intracellular concentration of calcium ions ([Ca2+]i): (a) a rapid response after direct microinjection of the messenger into the cells; (b) a slow variation of [Ca2+]i when cADPR is added to the cell culture medium; c) a progressive potentiation of [Ca2+]i increasing due to a depolarization. In fact, cADPR induces Ca2+ release from presynaptic and postsynaptic intracellular stores and plays an important role in the activity-dependent synaptic plasticity, including long-term depression [14]. In addition, enzymes able to catalyze the hydrolysis of cyclic ADP-ribose to ADP-ribose are expressed ubiquitously in the mouse brain. Specifically, wild-type mice show the highest cyclase activity in the hypothalamus, and then in the cerebellum, cerebrum and posterior pituitary [15]. Unfortunately, the lability of the N-1 glycosidic bond of cADPR towards enzymatic and/or non-enzymatic hydrolysis to ADP-ribose, even in a neutral aqueous solution, greatly hinders the studies aimed at elucidating its physiological role [16]. Several enzymes involved in the metabolism of cADPR have been described. Among them is the ubiquitous ADP-ribosyl cyclase, an enzyme first isolated from Aplysia Californica [17]. Using the Aplysia ADP-ribosyl cyclase many metabolite analogues of cADPR have been produced starting from NAD+ and NADP+ [18-21]. However, the specificity of the enzymatic cyclization mechanism drastically limits its applicability for enzymatic or chemo-enzymatic procedures. For this reason, to obtain new cADPR derivatives the exploitation of chemical synthetic strategies is still necessary. A lot of modifications regarding the northern and southern ribose as well as the purine base of cADPR have been proposed so far [22-23]. Matsuda and co-workers were the first who synthesized new analogues of the cADPR in which the adenine base was replaced by a hypoxanthine ring [24]. This kind of modification produced the cyclic inosine diphosphate ribose (cIDPR) 2 which proved to be stable in hydrolytic physiological conditions and showed significant Ca2+ mobilizing activity, thus fostering the synthesis of a variety of cIDPR analogues. In particular, the N1, N9 and C8-substituted cIDPR were the most interesting [24-33]. In the last few years several cIDPR analogues were also synthesized in our laboratory [34-37]. Among these, the N1-pentyl analogue cpIDP (3, Figure 1) [34] showed interesting activity on the PC12 cell line previously differentiated with the Nerve Growth Factor (NGF) (data not previously published). Starting from these data, we here report the synthesis and the preliminary biological activity of the new cyclic N1-pentylinosine monophosphate (cpIMP) (4, Figure 1), in which the pyrophosphate group of 3 was replaced by a monophosphate moiety connecting the southern ribose with the N1-pentyl chain. The here reported results significantly contribute to the understanding of the role played by the pyrophosphate moiety of cADPR and cIDPR analogues on the mobilization of Ca2+ ions. To date, such structure-activity relationship has only been poorly investigated [38-41]. We anticipate here that compounds 3 and 4 induce the same effect on Ca2+ mobilization in NGF-differentiated PC12 cells. In particular, both compounds produced a transient increase of intracellular concentration of Ca2+ when added to the cells, thus demonstrating their ability to cross the plasma membrane.

Results and Discussion

Chemistry

The key step for the preparation of all cADPR/cIDPR analogues is the macrocyclization via pyrophosphate bond formation, which is usually performed by joining the two phosphate moieties at the end of the multistep synthesis [24-29]. Similarly, the preparation of the new cpIMP derivative 4 could be performed by the cyclization of a monophosphate precursor via phosphodiester bond formation. For this purpose we investigated both the possible synthetic strategies (pathways A and B, Figure 2) in which the phosphate group (or its synthon) has been attached either on the end of the N1-pentyl chain (precursor A) or on the 5’-ribose position (precursor B).
Figure 2

Synthetic strategies explored in the cyclization step via phosphodiester bond formation.

Synthetic strategies explored in the cyclization step via phosphodiester bond formation. At first, to obtain the cpIMP (4) we followed the synthetic pathway A by using the strategy reported in Scheme 1 that employed the N1-ω-hydroxypentylinosine derivative 5 as the starting material [34]. Compound 5 was phosphorylated on the ω-hydroxyalkyl function by using the phosphitylating chloro-amidite agent 6. The reaction of 5 with 6 furnished the sole regioisomer 7 equipped with the reactive phosphorous(III) group. Unfortunately, the activation of the phosphoramidite function with 1H-tetrazole aimed at inducing the cyclization on the 5’-OH ribose function produced only a complex mixture. No traces of the target cyclic compound were detected after the usual phosphorous oxidation step.
Scheme 1

i) (iPr)2NP(OCE)Cl, DIPEA, THF, 1 h, rt; ii) 1) 1H-tetrazole, THF, 2) t-BuOOH, 2 h, rt; iii) 1) (iPr)2NP(OCE)2, 1H-tetrazole, THF, 2 h, rt, 2) t-BuOOH, 2 h, rt; iv) TEA/pyridine, 1:1 v/v, 16 h, rt; v) activating agent (EDC in DMF or DCC in DMF or MSNT in pyridine) 16 h, rt; vi) conc. aq NH4OH, MeOH, 50 °C, 16 h.

i) (iPr)2NP(OCE)Cl, DIPEA, THF, 1 h, rt; ii) 1) 1H-tetrazole, THF, 2) t-BuOOH, 2 h, rt; iii) 1) (iPr)2NP(OCE)2, 1H-tetrazole, THF, 2 h, rt, 2) t-BuOOH, 2 h, rt; iv) TEA/pyridine, 1:1 v/v, 16 h, rt; v) activating agent (EDC in DMF or DCC in DMF or MSNT in pyridine) 16 h, rt; vi) conc. aq NH4OH, MeOH, 50 °C, 16 h. This failure prompted us to use the alternative phosphitylating reagent bis(cyanoethyl)phosphoramidite 8, which, after the regioselective reaction with the 5’-hydroxyalkyl function of 5 led to the phosphotriester product 9 after the phosphorous oxidation with t-BuOOH. Starting from 9 we explored two synthetic routes, differing for the degree of esterification at the phosphate moiety, to achieve the cyclization of the 17-membered ring of 4. The treatment of 9 with a mixture of triethylamine/pyridine furnished the phosphodiester product 10 in almost quantitative yield. Instead, the complete removal of both 2-cyanoethyl groups of 9 with concentrated aqueous ammonia gave the phosphomonoester 11. Unfortunately, neither linear precursors 10 nor 11 underwent the expected cyclization step, even when treated with the most common phosphate activating agents (EDC, DCC, MSNT) in very diluted conditions. In our opinion, the target intramolecular cyclizations failed because of the poor mobility of the 5’-OH ribose function, as well as because of the unfavourable anti conformation of the N-glycosidic bond induced by the presence at the N1 position of the purine base of the bulky ω-phosphate adduct formed with the activating agent. For this reason, we decided to switch to the synthetic pathway B (Figure 2), in which the monophosphate group is installed at the 5’-ribose position. This strategy, reported in Scheme 2, used as the starting material the 5’-TBDMS-2’,3’-O-isopropylideneinosine (12). The protected inosine 12 was initially converted into the N1-dinitrophenyl derivative 13, which, after reaction with the 5-aminopentan-1-ol, furnished the N1-ω-hydroxypentylinosine derivative 14 [35]. This compound was acetylated on the ω-hydroxy function (compound 15) and then deprotected on the 5’-hydroxy function thus obtaining 16. The phosphorylation of the 5’-OH function of 16, by using the (iPr)2NP(OCE)2/t-BuOOH system, already used in the preparation of compound 9, furnished the 5’-O-phosphotriester inosine derivative 17. The treatment of 17 with concentrated aqueous ammonia allowed the removal of both the OCE phosphate protecting groups together with the acetate function, thus obtaining the key intermediate 18 as triethylammonium salt after HPLC purification. The derivate 18, dissolved in DMF at the final concentration of 2 mM was treated with EDC (1.2 equiv) and the reaction allowed to stand at room temperature for 48 h. From this mixture it was possible to isolate cyclic compound 19 (30% cyclization yield) whose structure was confirmed by NMR and high-resolution mass analyses. Eventually, the treatment of compound 19 with aqueous 20% TFA afforded the target compound 4.
Scheme 2

i) DNCB, K2CO3, DMF, 4 h, 80 °C; ii) 5-aminopentan-1-ol, DMF, 16 h, 50 °C; iii) Ac2O, pyridine, 2 h, rt, iv) NH4F, MeOH, 16 h, reflux; v) 1) (iPr)2NP(OCE)2, 1H-tetrazole, THF, 2 h, rt, 2) t-BuOOH, 2 h, rt; vi) conc. NH4OH(aq), MeOH, 50 °C, 16 h; vii) EDC, DMF; viii) TFA, H2O, 16 h, rt.

i) DNCB, K2CO3, DMF, 4 h, 80 °C; ii) 5-aminopentan-1-ol, DMF, 16 h, 50 °C; iii) Ac2O, pyridine, 2 h, rt, iv) NH4F, MeOH, 16 h, reflux; v) 1) (iPr)2NP(OCE)2, 1H-tetrazole, THF, 2 h, rt, 2) t-BuOOH, 2 h, rt; vi) conc. NH4OH(aq), MeOH, 50 °C, 16 h; vii) EDC, DMF; viii) TFA, H2O, 16 h, rt.

Ca2+-mobilizing activity of 3 and 4 in PC12 cells

To study the biological activity of compounds 3 and 4, we evaluated their effect on the mobilization of Ca2+ ions in PC12 cells differentiated with NGF. Interestingly, compounds 3 and 4 caused a rapid and transient increase of the intracellular [Ca2+] ([Ca2+]i) when added to the medium at the concentration of 100 nM (Figure 3). This pattern of response could be ascribed to the initial release of Ca2+ ions from the intracellular organelles followed by a depolarization-induced Ca2+ influx. The biological assays also confirmed that the cIDPR analogues 3 and 4 retained the ability to pass the plasma membrane of neuronal cells.
Figure 3

Effect of 3 and 4 on intracellular [Ca2+] in NGF-differentiated PC12 cells. (A) and (B): representative single-cell traces of the effect of 3 and 4 (100 nM) on [Ca2+]i,. (C): quantification of [Ca2+]i increase calculated, after the addition of each compound, as the percentage change of plateau/basal value. Each bar represents the mean (±S.E.M.) of the values obtained in three independent experimental sessions. For each experiment, 10 to 40 individual cells were monitored. *, P < 0.05 versus basal level.

Effect of 3 and 4 on intracellular [Ca2+] in NGF-differentiated PC12 cells. (A) and (B): representative single-cell traces of the effect of 3 and 4 (100 nM) on [Ca2+]i,. (C): quantification of [Ca2+]i increase calculated, after the addition of each compound, as the percentage change of plateau/basal value. Each bar represents the mean (±S.E.M.) of the values obtained in three independent experimental sessions. For each experiment, 10 to 40 individual cells were monitored. *, P < 0.05 versus basal level.

Conclusion

cADPR is a second messenger synthesized by neuronal cells that modulates the Ca2+ homeostasis in the nervous system [42]. Unfortunately, cADPR is characterized by a low ability to cross the plasma membranes. This behaviour hinders the studies on the effects of cADPR on cell functions. To overcome this limitation and to understand the role played by the pyrophosphate bridge on the biological activities of cADPR, we synthesized the lipophilic derivative cpIMP (4) in which the pyrophosphate group of 3 was replaced by a monophosphate moiety connecting the southern ribose with the N1-pentyl chain. We compared the activity of 4 in modulating the concentration of [Ca2+]i with that of the previously synthesized cpIDP (3). To study the effect of 3 and 4 on [Ca2+]i, these compounds were added to PC12 cells previously differentiated with NGF at the concentration of 100 nM. Both compounds caused a fast and transient increase in [Ca2+]i. This pattern of response could be ascribed to the initial release of Ca2+ from intracellular organelles followed by a depolarization-induced Ca2+ influx. The reported preliminary results indicate that 3 and 4 possess almost the same activity, thus indicating that the role of the pyrophosphate bridge is not stringent and that the introduction of an alkyl chain in the N1 position of the purine base improves the permeation of the cell membrane by passive diffusion or through an active uptake system expressed on the membrane.

Experimental

General

All solvents were dried by standard methods and all reactions were carried out under inert atmosphere (argon or nitrogen). All reagents were obtained and used from commercial sources (Sigma-Aldrich, Germany) without further purification. 1H and 13C NMR experiments were performed using a Varian Mercury Plus 400 MHz spectrometer in CD3OD, D2O, CDCl3 and acetone-d6 solvents. Chemical shifts are reported in parts per million (δ) relative to residual solvents signals: CD2HOD 3.31, HOD 4.80, (CD3)(CD2H)CO 2.09 for 1H NMR and CD3OD 49.0 for 13C NMR. 31P NMR experiments were carried out on a Varian Unity INOVA 500 MHz instrument in CD3OD solvent using 85% H3PO4 as an external standard (0 ppm). High performance liquid chromatography (HPLC) was performed using a Jasco UP-2075 Plus pump equipped with a Jasco UV-2075 Plus UV detector and a 4.8 × 150 mm C-18 reversed-phase column (particle size 5 µm) eluted with a linear gradient of CH3CN in 0.1 M triethylammonium bicarbonate (TEAB) buffer (from 0 to 50% in 45 min, flow 1.3 mL/min). UV spectra were recorded on a Jasco V-530 UV spectrophotometer. High-resolution MS spectra were recorded on a Bruker APEX II FT-ICR mass spectrometer using the electrospray ionization (ESI) technique. Column chromatography was carried out on silica gel-60 (Merck, 0.063–0.200 mm) or on C-18 reversed-phase silica gel-60 (Merck, 0.040–0.063 mm). Analytical TLC analyses were performed using F254 silica gel plates (0.2 mm thick, Merck). TLC spots were detected under UV light (254 nm).

Cell cultures and [Ca2+]i measurements

PC12 cells, grown on plastic dishes in RPMI medium composed of 10% horse serum, 5% FBS, 100 UI/mL penicillin and 100 μg/mL streptomycin, were differentiated in neurons with NGF (50 ng/mL; 7 days). Cells were cultured in an atmosphere of 5% CO2. The culture medium was changed every 2 days. For microfluorimetric studies with Fura 2-AM, cells were seeded on glass coverslips (Fisher, Springfield, NJ, USA) coated with poly-L-lysine (5 μg/mL) (Sigma, St. Louis, Missouri, USA) and used at least 12 h after seeding. Intracellular Ca2+ concentration ([Ca2+]i) was measured by single cell computer-assisted video QImaging [43]. Briefly, differentiated PC12 cells cultured on poly-L-lysine-coated glass coverslips were loaded with 10 µM Fura-2AM for 1 h at 22 °C in Krebs–Ringer saline solution containing the following: 5.5 mM KCl, 160 mM NaCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 10 mM glucose, and 10 mM HEPES-NaOH, pH 7.4. At the end of the loading period, the coverslips were placed in a perfusion chamber (Medical System, Greenvale, NY, USA), mounted on a Zeiss Axiovert 200 microscope (Carl Zeiss, Germany) equipped with a FLUAR 40X oil objective lens. The experiments employed a digital imaging system composed of a MicroMax 512BFT cooled CCD camera (Princeton Instruments, Trenton, NJ, USA), LAMBDA 10-2 filter wheeler (Sutter Instruments, Novato, CA, USA), and Meta-Morph/MetaFluor Imaging System software (Universal Imaging, West Chester, PA, USA). After loading, the cells were illuminated alternately at 340 and 380 nm by a Xenon lamp. The emitted light was passed through a 512 nm barrier filter. Fura-2AM fluorescence intensity was measured every 3 s. Forty to sixty-five individual cells were selected and monitored simultaneously from each cover slip. Results are presented as the cytosolic Ca2+ concentration. Calibrations used the relation of Grynkiewicz et al. [44] assuming that the KD for Fura-2AM was 224 nM. Structural characterizations.
  37 in total

Review 1.  Cyclic ADP-ribose as a potential second messenger for neuronal Ca2+ signaling.

Authors:  H Higashida; M Hashii; S Yokoyama; N Hoshi; K Asai; T Kato
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

2.  A novel membrane-permeant cADPR antagonist modified in the pyrophosphate bridge.

Authors:  N Qi; K Jung; M Wang; L X Na; Z J Yang; L R Zhang; A H Guse; L H Zhang
Journal:  Chem Commun (Camb)       Date:  2011-07-22       Impact factor: 6.222

3.  Highly Stereoselective Synthesis of Lamivudine (3TC) and Emtricitabine (FTC) by a Novel N-Glycosidation Procedure.

Authors:  Maria Federica Caso; Daniele D'Alonzo; Stefano D'Errico; Giovanni Palumbo; Annalisa Guaragna
Journal:  Org Lett       Date:  2015-05-12       Impact factor: 6.005

4.  Synthesis and biological evaluation of novel membrane-permeant cyclic ADP-ribose mimics: N1-[(5''-O-phosphorylethoxy)methyl]-5'-O-phosphorylinosine 5',5''-cyclicpyrophosphate (cIDPRE) and 8-substituted derivatives.

Authors:  Xianfeng Gu; Zhenjun Yang; Liangren Zhang; Svenja Kunerth; Ralf Fliegert; Karin Weber; Andreas H Guse; Lihe Zhang
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

5.  Cyclic adenosine 5'-diphosphoribose (cADPR) mimics used as molecular probes in cell signaling.

Authors:  Liangren Zhang; Jianbo Yue; Li-He Zhang
Journal:  Chem Rec       Date:  2015-02-24       Impact factor: 6.771

6.  Identification of cyclic ADP-ribose-dependent mechanisms in pancreatic muscarinic Ca(2+) signaling using CD38 knockout mice.

Authors:  Y Fukushi; I Kato; S Takasawa; T Sasaki; B H Ong; M Sato; A Ohsaga; K Sato; K Shirato; H Okamoto; Y Maruyama
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

Review 7.  Chemistry of cyclic ADP-ribose and its analogs.

Authors:  Satoshi Shuto; Akira Matsuda
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

8.  Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphosphate.

Authors:  D L Clapper; T F Walseth; P J Dargie; H C Lee
Journal:  J Biol Chem       Date:  1987-07-15       Impact factor: 5.157

9.  Synthesis of cyclic adenosine 5'-diphosphate ribose analogues: a C2'endo/syn "southern" ribose conformation underlies activity at the sea urchin cADPR receptor.

Authors:  Christelle Moreau; Gloria A Ashamu; Victoria C Bailey; Antony Galione; Andreas H Guse; Barry V L Potter
Journal:  Org Biomol Chem       Date:  2010-10-25       Impact factor: 3.876

10.  Design and synthesis of cyclic ADP-4-thioribose as a stable equivalent of cyclic ADP-ribose, a calcium ion-mobilizing second messenger.

Authors:  Takayoshi Tsuzuki; Natsumi Sakaguchi; Takashi Kudoh; Satoshi Takano; Masato Uehara; Takashi Murayama; Takashi Sakurai; Minako Hashii; Haruhiro Higashida; Karin Weber; Andreas H Guse; Tomoshi Kameda; Takatsugu Hirokawa; Yasuhiro Kumaki; Barry V L Potter; Hayato Fukuda; Mitsuhiro Arisawa; Satoshi Shuto
Journal:  Angew Chem Int Ed Engl       Date:  2013-05-13       Impact factor: 15.336

View more
  3 in total

1.  Isatins Inhibit N5-CAIR Synthetase by a Substrate Depletion Mechanism.

Authors:  Cale C Streeter; Qian Lin; Steven M Firestine
Journal:  Biochemistry       Date:  2019-04-17       Impact factor: 3.162

2.  Second messenger analogues highlight unexpected substrate sensitivity of CD38: total synthesis of the hybrid "L-cyclic inosine 5'-diphosphate ribose".

Authors:  Joanna M Watt; Richard Graeff; Mark P Thomas; Barry V L Potter
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

3.  New Linear Precursors of cIDPR Derivatives as Stable Analogs of cADPR: A Potent Second Messenger with Ca2+-Modulating Activity Isolated from Sea Urchin Eggs.

Authors:  Stefano D'Errico; Emy Basso; Andrea Patrizia Falanga; Maria Marzano; Tullio Pozzan; Vincenzo Piccialli; Gennaro Piccialli; Giorgia Oliviero; Nicola Borbone
Journal:  Mar Drugs       Date:  2019-08-17       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.